OS THERAPIES INCORPORATED SEC Filings

OS Therapies Inc. filed a report showing that senior officer Robert Petit, the company’s Chief Medical Officer and Chief Scientific Officer, received a new equity award. On October 21, 2025, he was granted stock options to purchase 500,000 shares of OS Therapies common stock at an exercise price of $1.80 per share.

The options are scheduled to vest in full on the one-year anniversary of the grant date, as long as he is still employed by OS Therapies at that time. After this transaction, Petit also holds 200,000 shares of OS Therapies common stock directly, in addition to the newly granted options.

OS Therapies Inc. reported an insider equity award for its President and CEO, who is also a director. On October 21, 2025, the executive received stock options to purchase 1,950,000 shares of OS Therapies common stock at an exercise price of $1.8 per share. These options expire on October 21, 2035 and vest in full on the one-year anniversary of the grant date, as long as the executive remains employed by the company on that date.

Following this grant, the reporting person holds 2,473,000 shares of common stock directly, in addition to the newly granted 1,950,000 stock options, reflecting a significant personal equity stake in OS Therapies.

OS Therapies Inc director reports stock option grant. A director of OS Therapies Inc (OSTX) reported receiving stock options to purchase 140,000 shares of the company’s common stock on October 21, 2025, at an exercise price of $1.80 per share. The options vest in full on the one-year anniversary of the grant date, as long as the director is still serving on the board at that time, and are scheduled to expire on October 21, 2035.

OS Therapies Inc. director receives new stock option grant. A reporting person serving as a director of OS Therapies Inc. (ticker OSTX) was granted stock options on October 21, 2025 to purchase 140,000 shares of the company’s common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, as long as the individual continues to serve as a director on that date, and are scheduled to expire on October 21, 2035. Following this grant, the director beneficially owns 140,000 stock options directly.

OS Therapies Inc director reports new stock option grant and holdings. On October 21, 2025, director John Ciccio was granted stock options to buy 140,000 shares of OS Therapies Inc common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, if he is still serving as a director on that date, and expire on October 21, 2035.

After the reported transactions, he beneficially owns 435,835 shares of common stock indirectly through Mill River Partners LLC and 20,000 shares directly, in addition to the 140,000 stock options held directly.

OS Therapies Inc. reported that its Chief Financial Officer received a new stock option grant. On October 21, 2025, the reporting person was granted options to purchase 200,000 shares of OS Therapies common stock at an exercise price of $1.8 per share, under a stock option award agreement.

The options vest in full on the one-year anniversary of the grant date, as long as the individual is still serving as an employee on that date. Following this grant, the reporting person holds 109,375 shares of common stock directly and 200,000 stock options directly.

OS Therapies Inc director Avril McKean-Dieser reported new equity awards and current holdings. As of the reported transactions, the director beneficially owns 5,000 shares of OS Therapies common stock in direct ownership. On October 21, 2025, the director was granted stock options to purchase 140,000 shares of common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, provided the director is still serving on the board at that time, and expire on October 21, 2035. The grant reflects part of the director’s equity-based compensation.

OS Therapies (OSTX) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $6.9 million for the quarter and $15.3 million year‑to‑date, driven by higher research and development ($7.6 million YTD) and general and administrative expenses ($9.2 million YTD). Cash was $1.88 million, and management stated these conditions raise “substantial doubt” about the company’s ability to continue as a going concern.

Total assets rose to $9.0 million, reflecting the April acquisition of HER2 immuno‑oncology assets from Ayala, recorded at a fair value of $6.86 million, largely paid in common stock. The company recognized $236 thousand of amortization on these intangibles year‑to‑date. Stockholders’ equity improved to $3.64 million from a deficit at year‑end 2024, aided by conversions of preferred stock and warrant activity.

Operating cash burn was $10.5 million YTD, partly offset by $7.3 million in financing cash inflows, including warrant exercises and a preferred stock raise. The warrant liability declined to $0 with a $1.42 million favorable fair value change. Shares outstanding were 35,214,352 as of November 14, 2025.

OS Therapies (OSTX) reported results of its 2025 annual meeting and stockholders approved an amendment to the company’s 2023 Incentive Compensation Plan. The meeting was held on October 21, 2025, with 20,516,482 shares present in person or by proxy out of 31,998,288 shares entitled to vote, establishing a quorum.

Votes were recorded on director nominees and other proposals as detailed, and the amended plan text was filed as Exhibit 10.1. Routine meeting items, including proposals receiving broker non-votes, were also tallied.